CoChat

Small Molecule Activation of Adaptive Gene Expression: Tilorone or Its Analogs Are Novel Potent Activators of Hypoxia Inducible Factor‐1 That Provide Prophylaxis against Stroke and Spinal Cord Injury

Open access
Ratan, Rajiv R., Siddiq, Ambreena, Aminova, Leila, Langley, Brett, McConoughey, Stephen, Karpisheva, Ksenia, Lee, Hsin‐Hwa, Carmichael, Thomas, Kornblum, Harley, Coppola, Giovanni, Geschwind, Daniel H., Hoke, Ahmet, Smirnova, Natalya, Rink, Cameron, Roy, Sashwati, Sen, Chandan, Beattie, Michael S., Hart, Ron P., Grumet, Martin, Sun, Dongming, Freeman, Robert S., Semenza, Gregg L., Gazaryan, Irina · 2008 · Annals of the New York Academy of Sciences
Cited by 57

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

A major challenge for neurological therapeutics is the development of small molecule drugs that can activate a panoply of downstream pathways without toxicity. Over the past decade our group has shown that a family of enzymes that regulate posttranscriptional and transcriptional adaptive responses to hypoxia are viable targets for neuronal protection and repair. The family is a group of iron, oxygen, and 2‐oxoglutarate‐dependent dioxygenases, known as the HIF prolyl 4‐hydroxylases (HIF PHDs). We have previously shown that pluripotent protection offered by iron chelators is mediated, in part, via the ability of these agents to inhibit the HIF PHDs. Our group and others have implicated the transcriptional activator HIF‐1 in some of the salutary effects of iron chelation‐induced PHD inhibition. While some iron chelators are currently employed in humans for conditions such as hemochromatosis, the diverse utilization of iron in physiological processes in the brain makes the development of HIF activators that do not bind iron a high priority. Here we report the development of a high throughput screen to develop novel HIF activators and/or PHD inhibitors for therapeutic use in the central nervous system (CNS). We show that tilorone, a low‐molecular weight, antiviral, immunomodulatory agent is the most effective activator of the HIF pathway in a neuronal line. We also show that tilorone enhances HIF protein levels and increases the expression of downstream target genes independent of iron chelation and HIF PHD inhibition in vitro. We further demonstrate that tilorone can activate an HIF‐regulated reporter gene in the CNS. These studies confirm that tilorone can penetrate the blood–brain barrier to activate HIF in the CNS. As expected from these findings, we show that tilorone provides effective prophylaxis against permanent ischemic stroke and traumatic spinal cord injury in male rodents. Altogether these findings identify tilorone as a novel and potent modulator of HIF‐mediated gene expression in neurons with neuroprotective properties.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1196/annals.1427.033

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

Metadata

Authors
Ratan, R. R., Siddiq, A., Aminova, L., Langley, B., McConoughey, S., Karpisheva, K., Lee, H., Carmichael, T., Kornblum, H., Coppola, G., Geschwind, D. H., Hoke, A., Smirnova, N., Rink, C., Roy, S., Sen, C., Beattie, M. S., Hart, R. P., Grumet, M., Sun, D., Freeman, R. S., Semenza, G. L., & Gazaryan, I.
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
2008-12
Volume
1147
Issue
1
Pages
383-394
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
OpenAlex
W2049166204
Cited by
57
References
3
FWCI
1.72
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.